| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | Sunitinib | FIMM | pan-cancer | AAC | 0.015 | 0.9 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | PHA-793887 | GDSC1000 | pan-cancer | AAC | -0.0021 | 0.9 |
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | -0.0022 | 0.9 |
| mRNA | StemRegenin 1 | CTRPv2 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | XMD8-92 | GDSC1000 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | -0.002 | 0.9 |